Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Article | IMSEAR | ID: sea-209559

ABSTRACT

Introduction: Although there are many methods in malaria diagnoses e.g., quatitative buffy coat (QBC), rapid diagnosis tests (RDTs), serological tests and molecular diagnosis methods such as PCR, but microscopy still remains the gold standard for malaria diagnosis. Estimation of malaria parasite density can be carried out by using assumed white blood cells (WBC) and red blood cells (RBC) counts. Objective: The aims of this study were to determine malaria parasite densities calculated by Original Research Article assumed WBC and RBC counts; and to compare their reliability with absolute WBC and RBC counts. Methods: The clinical presentations and laboratoryfindings of specimens collectedfrom 512 uncomplicated falciparum and vivax malaria patients admitted to Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand were utilized and analysed for estimation of malaria parasite densities by using different formulas.Results: Parasite densities calculated by WHO recommended assumed WBC of 8,000 /μL, and assumed RBC counts of 4.7x106-6.1x106/μL and 4.2x106-5.4x106 /μL for males and females respectively led to overestimation, and resulted in low reliability when compared to the absolute WBC and RBC counts.Parasite densities calculated by assumed WBC of 5,900/μL in thick blood; by assumed RBC of 4.8x106/μL for malesand 4.3x106/μLfor femalesin thin blood film respectively gave more precise estimation.Conclusion: Assumed WBC and RBC counts for calculating malaria parasite densities haveto be adjusted to use in Thailand for more precise estimation. Parasite densities calculated by assumed WBC and RBC used in other malaria endemic countries might need further re-evaluation

2.
Annals of the Academy of Medicine, Singapore ; : 303-314, 2016.
Article in English | WPRIM | ID: wpr-353688

ABSTRACT

<p><b>INTRODUCTION</b>Chloroquine, in combination with primaquine, is used as the firstline treatment for uncomplicated P. vivax malaria in Thailand. In view of the declining efficacy of chloroquine in many P. vivax endemic areas, the possibility of emergence of chloroquine- resistant P. vivax in Thailand is a concern. The aim of this study was to assess the trends in therapeutic efficacy of chloroquine and primaquine for the treatment of uncomplicated P. vivax malaria and to assess the utility of parasite clearance times as a measure of efficacy.</p><p><b>MATERIALS AND METHODS</b>This study consisted of: 1) review of medical records of patients who were hospitalised for a period during their treatment for uncomplicated P. vivax malaria at the Hospital for Tropical Diseases, Bangkok, Thailand between 2004 and 2013. Treatment consisted of chloroquine (1500 mg base administered over 3 days) or chloroquine (as before) plus primaquine (15 to 30 mg base/daily for 14 days from day 2); and 2) systematic review of the literature in English to assess current standards in the reporting of parasite clearance times.</p><p><b>RESULTS</b>The 28-day cure rate was 99.1%. The range of median parasite clearance time over the 10-year period was 46 to 59 hours, and there was statistical evidence for an increasing trend in parasite clearance times between 2009 and 2013. Heterogeneity was noted among previous chloroquine efficacy studies in the measurement and reporting of parasite clearance.</p><p><b>CONCLUSION</b>The treatment of P. vivax infection with a combination of chloroquine and primaquine has remained efficacious in Thailand. Increasing rates of parasite clearance in a population over time may be a useful early warning mechanism for the emergence of chloroquine resistance. The utility of monitoring time-trends in parasite clearance to detect resistance may be enhanced if parasite clearance measurements are standardised.</p>


Subject(s)
Humans , Antimalarials , Therapeutic Uses , Chloroquine , Therapeutic Uses , Drug Resistance, Microbial , Drug Therapy, Combination , Malaria, Vivax , Drug Therapy , Plasmodium vivax , Primaquine , Therapeutic Uses , Thailand , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL